Metraipolis › archive › dc_b1eddbf2c880

Cost-effectiveness of first-line encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer — Europe PMC PMID:41797900

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41797900
DOI
10.1016/j.isci.2026.114977
License (as archived)
solo-consultazione
Archived
2026-11-05T23:35:13.865Z
SHA-256 of the archived text
4b14094f26706172ee1fbbf687d3f4f989b047ee4a2035436beeb530e92c958c
Stable URL of this page
https://metraipolis.com/documento/dc_b1eddbf2c880

How to cite

Cost-effectiveness of first-line encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer — Europe PMC PMID:41797900 — Europe PMC (en), https://europepmc.org/article/MED/41797900 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b1eddbf2c880 (Metraipolis archive dc_b1eddbf2c880, sha256 4b14094f26706172ee1fbbf687d3f4f989b047ee4a2035436beeb530e92c958c)
BibTeX
@misc{dcb1eddbf2c880,
  title = {Cost-effectiveness of first-line encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer — Europe PMC PMID:41797900},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41797900},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b1eddbf2c880; sha256 4b14094f26706172ee1fbbf687d3f4f989b047ee4a2035436beeb530e92c958c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41797900. Agents can read the archived copy with the MCP tool read_document.